The NovAliX/Kyowa Hakko Kirin Alliance Will Commence a Fragment-Based Drug Discovery Project Targeting an Important Protein/Protein Interaction

NovAliX SAS announced today that it has entered into a fragment-based drug discovery project with Kyowa Hakko Kirin Co., Ltd., Japan. This is a continuation of the alliance announced on January 14 of this year and builds upon the positive results already generated by the NovAliX biophysical platform.

The companies will commence research against a new clinically significant target involving the discovery of novel small molecules that modulate protein-protein interaction. First, NovAliX will generate lead candidates using its Graffinity® screening platform. The ensuing "hits" will be elaborated by NovAliX' in-house teams of biophysical and chemistry experts. The biophysical toolbox encompasses a broad spectrum of instrumental techniques employed iteratively to support the activities of synthetic organic, computational and medicinal chemists.

Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.

Stephan Jenn, President of NovAliX, stated, ”We in NovAliX are highly excited by this important development in our relationship with Kyowa Hakko Kirin. The collaboration with a leading Japanese pharmaceutical company underlines the value offered by the NovAliX integrated drug discovery platforms; platforms designed and proven to deliver not only hits and but also optimized lead compounds. The extension of the drug discovery alliance to another target validates our capabilities.”